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Abstract 
Background: Lymphadenitis is the most common complication of BCG vaccination in children. 
Interferon-gamma (IFN-γ) plays a key role in immune response to Mycobacterial infections. In this 
study, the relationship of serum levels of IFN-γ and its receptor (CD119) to development of Bacillus 
Calmette Guerin (BCG) axillary lymphadenopathy was investigated.  
Materials and Methods: In this case-control study, 45 children with axillary lymphadenopathy and 45 
healthy children matched by age and sex were included. Two ml peripheral blood was collected in 
tubes containing anticoagulants. Then, level of IFN-γ was measured by ELISA and the level of 
CD119 expression in the peripheral blood mononuclear cell (PBMC) was measured by flow 
cytometry. Data were analyzed using SPSS software version 22.0.  
Results: Totally, 90 children were enrolled in this study, which consisted of 30 girls and 60 boys. The 
mean age of participants was 14.5±6.5 months in case group and 15.2±7.1 months in control group, 
respectively (p=0.61). The level of IFN-γ was significantly lower in case group than in control group 
(p<0.001), but no significant difference was observed in PBMC percentage between the two groups 
(p>0.05). There was no significant relationship of age and sex to BCG (INF and PBMC) 
lymphadenopathy (p>0.05). 
Conclusion: Based on the results, IFN-γ level was significantly lower in the BCG lymphadenopathy 
group than in the control group. Levels of IFN-γR (CD119 cellular level in PBMC) in two groups did 
not show a significant relationship. 
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1- INTRODUCTION 
       Tuberculosis (TB) due to 
Mycobacterium tuberculosis (Mtb) is 
currently one of the main health issues 
across the globe (1). Data from 202 
countries (the Global Tuberculosis Report 
2014) indicated the presence of TB in all 
regions of the world (2). Most patients 
with Mtb infection exhibit no clinical 
disease symptoms and less than 10% of 
them have history of developing clinical 
TB (3). Bacillus Calmette Guerin (BCG) 
vaccine is a live attenuated vaccine (strain 
of Mycobacterium bovis) that has been 
administered worldwide to prevent TB (4).  
BCG was developed by Albert Calmette 
and Camille Guerin in France between 
1908 and 1921. According to World 
Health Organization (WHO) 
recommendation, BCG vaccination should 
be accomplished for all infants in several 
countries, especially in highly endemic 
countries or countries neighboring such 
regions (5). The efficacy of BCG vaccine 
to prevent TB is indefinite; this vaccine 
protects against the meningeal/miliary TB 
in childhood TB but not against adult TB 
(4). Although BCG vaccination is safe for 
most children (6), it may lead to certain 
complications such as abscesses and 
cellulitis at the site of inoculation and 
regional lymphadenitis (7). The most 
widespread complication of BCG 
vaccination is lymphadenitis (4).  
BCG vaccine induced lymphadenitis refers 
to the enlargement of ipsilateral regional 
lymph node (particularly the axillary 
lymph nodes and rarely neck lymph nodes) 
following BCG vaccination so that it can 
be touched, without local/systemic signs of 
inflammation (1). In the normal course of 
the disease, BCG lymphadenopathy can be 
self-limiting within a few weeks or 
progress and develop into purulent 
lymphadenitis (4). The prevalence of 
lymphadenopathy, purpura lymphadenitis 
and fistulatization in certain regions of Iran 
has been reported to be 2.2%, 0.5% and 
1.8%, respectively (8). The immune 
response to BCG lymphadenitis has not yet 
been exactly explained. Similar to the 
primary infection, if a person vaccinated 
with BCG is contaminated with Mtb, a 
severe cellular immune response will 
occur and the infection will be controlled. 
Therefore, the aim of immunization with 
BCG is not to prevent Mtb infection, but to 
localize the infection and prevent its 
spread (9). Generally, the cellular response 
to mycobacterial infection is exhibited 
through IFN-γ produced by T cells, which 
activates macrophages to kill Mtb (10).  
IFN-γ, which is the most important 
cytokine, is from type II family. IFN-γ is 
mainly produced by Th1 (CD4 and CD8), 
natural killer (NK) cells and natural killer 
T (NKT) cells (11). Recently, IFN-γ 
release assays (IGRAs) have been 
developed to detect latent tuberculosis 
infection. This series of experiments 
measures individual immune response by 
measuring the release rate of IFN-γ from T 
cells after stimulation by Mtb-specific 
antigens (ESAT-6 and CFP-10).  
These antigens are absent in BCG and 
most peripheral mycobacteria (12). The 
use of IGRA in children is controversial 
yet remains widely accepted (13). 
Interferon Gamma Receptor-1 (IFN-γR1), 
also called CD119, is a protein in humans 
transcribed by the IFNGR1 gene (14). It 
has been reported that mice with IFN-γ- or 
the IFN-γR-deficiency are highly 
predisposed to infection with tuberculosis-
causing organisms (15); but the effect of 
IFN-γ in human macrophages remains 
controversial (10). Although many clinical 
studies have been conducted on IFN 
production in TB, studies of IFN-
responsiveness are rare. The functional and 
genetic defects of the IFN-γR have not 
been identified in BCG lymphadenitis and 
no convincing clear evidence is available 
to approve that IFNγ contributes greatly to 
most clinical TB infections (16). 
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Therefore, the aim of this study was to 
investigate the relationship of IFN-γ levels 
and the cellular expression levels of serum 
CD119 to the development of BCG 
axillary lymphadenopathy in patients and 
controls. The results of this study are 
expected to help clinicians to predict 
lymphadenitis, prevent indiscriminate 
treatments and prescription of unnecessary 
antibiotics, and adopt specific treatments. 
2- MATERIALS AND METHODS 
2-1. Study design and population 
      This is a case-control analytical study 
conducted from April 2017 to March 2019. 
Samples were selected by available 
sampling from patients referring to Imam 
Ali Clinic, Shahrekord, Iran, during the 
period 2016 to 2019. Per each patient, a 
healthy child was included as a control 
among patients who referred to Imam Ali 
clinic in Shahrekord who were included in 
the study. According to previous studies, 
45 children with axillary lymphadenopathy 
and 45 healthy children were enrolled (17, 
18). The control group was matched by 
age and sex with the case group.  
2-2. Laboratory measurements 
Blood samples were collected from all 
samples and serum IFN-γ was measured 
by ELISA. The cellular expression of the 
CD119 was measured using specific 
antibody with flow cytometry device. 
2-3. Intervention 
2-3-1. Vaccination methods 
The dry BCG vaccine was injected at an 
interval of one-third upper and lower thirds 
of the arm at 0.05 dosage and for the two 
groups methods of vaccination were the 
same. 
2-3-2. The steps of measuring serum 
IFN-γ levels by enzyme linked 
immunosorbent assay (ELISA) 
Blood samples (3 ml) were centrifuged for 
1000-1200 minutes to conduct an ELISA 
test in clotted gelated tubes. Serum was 
stored at -70 °C in microtubes until 
conduction of ELISA. Hemolytic or 
lipemic sera or serum samples with rare 
diseases were excluded and replaced with 
other appropriate samples. Positive control 
was considered to be PHA 
(phytohaemagglutinin, 1 mA), negative 
control to be antigen-free and the test to 
contain specific bacillus antigens was 
considered (19). The experiment steps 
were followed according to the 
instructions of an Elisa kit (R & D, 
Minneapolis, MN, USA), and continued 
via preparation of the standard solution, 
IFN-γ antibody and streptavidin-HRP. An 
incubation period at 37 °C was done and 
the wells were washed with buffer four 
times, each time for 30 s. After adding 
chromogenes A and B to all wells, 10 min 
of incubation, and finally adding of a 
stopper, optical absorbance was read at 
450 nm wavelength using stat fax 2100 
ELISA reader (6). 
2-3-3. Flow cytometry analysis to 
determine IFNγ-R1 (CD119) marker on 
PBMC 
The separation of peripheral blood 
mononuclear cells (PBMCs) was 
performed on healthy and patient 
participants using the Ficoll method and 
concentration gradient. Two ml of 
peripheral blood containing anticoagulant 
was diluted in an equal amount of PBS 
(phosphate buffered saline), and slowly 
poured into two ml of Ficoll solution 
(Inno-train, Germany). After 
centrifugation, the lymphocyte zone was 
inserted between the plasma and the Ficoll 
layers based on the density gradient. This 
layer was was isolated carefully. The 
isolated monoclonal cells were washed 
with PBS solution in three steps to remove 
all of the extra substances and proteins. To 
determine the frequency of the CD119 
marker, specific anti-monoclonal 
antibodies against CD119 cellular level 
were used. To all the tubes, about 1 million 
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PBMC cells were added and then 3 Landa 
of the respective antibody was added to the 
test tubes. The negative control tube 
contained blood without labeled 
antibodies. All tubes were incubated for 20 
min at room temperature. Then 1000 μl of 
non-sterile PBS was added to each tube. 
After centrifugation, a solution was 
obtained containing approximately 
1,000,000 cells stained with fluorochrome 
antibodies. The tubes were promptly read 
by a flow cytometry device (Cyflow 
PARTEC). Anti-human CD119-PE 
(eBioscience Company) was used. CD119 
was reported as PBMC percentage. 
2-4. Ethical consideration 
This research project was approved by the 
Ethics Committee of Research and 
Technology Department, affiliated with 
Shahrekord University of Medical 
Sciences with ethical number: 
IR.SKUMS.REC.1396.184 and written 
consent to participate in the study was 
obtained from parents. 
2-5. Inclusion and exclusion criteria 
Case group was 45 children aged 7-36 
months that developed axillary 
lymphadenopathy on the site of injection 
following BCG vaccination. The inclusion 
criteria were children with axillary 
lymphadenopathy (enlargement of the 
armpit lymph nodes without fever or other 
clinical symptoms), and a history of BCG 
vaccination (13). Patients were excluded 
from the study if they had 
immunocompromised disorders and family 
(sibling) history of immunodeficiency 
(BCGitis and history of 
immunodeficiency) or withdrew from 
participation in the study.  
2-6. Data Analyses  
All data were recorded in the checklist and 
entered into the SPSS software version 
22.0. Quantitative variables with normal 
distribution were expressed as mean ± 
standard deviation (SD), and quantitative 
variables with non-normal distribution as 
median and interquartile range. 
Comparison of age between the two 
groups was done by independent t-test and 
comparison of IFN-γ level and CD119 
expression levels between the two groups 
was carried out by the Mann-Whitney test. 
P-value less than 0.05 were statistically 
significant. 
3- RESULTS 
       In this study, the following results 
were obtained regarding the relationship of 
IFN-γ levels and serum CD119 expression 
to the occurrence of BCG induced axillary 
lymphadenopathy in Shahrekord, Iran. A 
total of 90 children aged 7-36 months with 
an average age of 14.9 ± 6.8 months were 
included in this study, of whom 45 were 
assigned to case group (children with 
axillary lymphadenopathy), and 45 to 
control group (healthy children). Each 
group consisted of 15 girls and 30 boys.  
The mean age was 14.5 ± 6.5 months in 
the case group and 15.2 ± 7.1 months in 
the control group, without any statistically 
significant difference (P=0.61). The results 
of the comparison of the studied variables 
including IFN-γ and PBMC percentage are 
shown in Table.1. As seen, the mean IFN 
of the case group was significantly lower 
than that of the control group (P <0.001). 
There was no significant difference in 
PBMC percentage between the case and 
control groups (P>0.05). Furthermore INF 
and PBMC percentage were not 
significantly associated with age and 
gender in the current study (P<0.05). 
 
 
   
 
 
Zamani et al. 
Int J Pediatr, Vol.7, N.12, Serial No.72, Dec. 2019                                                                                         10599 
Table-1: Results of vaccine response parameters in case and control groups (n=90). 
Variables 
Case group (n=45) Control group (n=45) 
P-value 
Median (interquartile range) Median (interquartile range) 
Interferon gamma 
concentration (ng/ml) 
22.6 (15.7-66.25) 163.4 (68.7-294.5) <0.001 
PBMC 62.55 (47.15-69.25) 62.3 (53.4-68.8) 0.884 
PBMC: peripheral blood mononuclear cells. Case group: children with axillary lymphadenopathy, Control 
group: healthy children.  
   
4- DISCUSSION 
      In this study, the relationship of serum 
levels of IFN-γ and its receptor (CD119) to 
develop BCG axillary lymphadenopathy 
was investigated. In the present study, the 
mean age of children with BCG 
lymphadenopathy was 9.9 ± 8.6 months. 
There was no significant relationship of 
age and sex to BCG (INF and PBMC) 
lymphadenopathy (P>0.05). Consistent 
with the present study, in Behjati and 
Ayatollahi’s study (8), there was no 
significant difference in the incidence of 
lymphadenopathy between boys and girls. 
However, in one study the prevalence of 
disseminated BCG infection was reported 
to be higher in males; however, the sample 
size of that study was extremely low (20).  
Various factors such as age at vaccination, 
vaccine injection site, vaccine preparation, 
immune system failure, and race, different 
strains of BCG, and manufacturer and 
individual characteristics of the population 
studied were factors influencing the 
incidence of complications of BCG 
vaccine (including lymphadenopathy and 
lymphadenitis). Incorrect technique of 
intradermal injection and excess dose 
increase the likelihood of developing 
complications (21-23). In the present 
study, IFN-γ was significantly lower in 
BCG lymphadenitis group than in control 
group. In the majority of studies, IFN-γ 
levels have been higher in patients with 
active TB compared to those with latent 
TB (24), and in some studies, an opposite 
finding has been obtained (25). Kim et al. 
reported that in patients with positive 
IGRA test, IFN-γ levels in those with TB 
were significantly higher than those 
without TB, and therefore suggested IGRA 
as a method for the diagnosis of TB (26). 
Following TB infection, despite 
phagocytosis by macrophages, the bacilli 
that have been introduced into the 
macrophages continue to proliferate in the 
early stages, and are induced only after the 
antigen is supplied to T cells (CD4 and 
CD8), IFN-γ and IL-2 (27). Macrophages 
are contaminated and monocytes are 
activated in the presence of IFN-γ which 
leads to intracellular bacterial death by 
increasing the phagosome fusion with 
lysosomes (12). The results of this study 
indicating the lower level of IFN-γ in 
children with BCG lymphadenitis than in 
those without lymphadenitis are consistent 
with previous studies. However, in the 
present study, the effects of BCG vaccine 
but not active TB have been investigated.  
In some studies, production of IFN-γ after 
BCG vaccine has not been directly related 
to resistance against the disease, but has 
served as an important predictor of the 
effectiveness of the vaccine and the 
severity of the disease (28). Similar to the 
present study, in a study in 74 TB cases in 
Iraq; the mean IFN-γ serum level 
significantly decreased (26.92±5.29 pg/ml) 
in comparison to healthy controls 
(28.40±10.73pg/ml). A decrease was also 
observed in IFN-γ level during TB 
infection (23), but in the TB patients aged 
15-60 years, mean of IFN-γ was 
The Relationship of Serum Levels of Gamma Interferon and its Receptor 
Int J Pediatr, Vol.7, N.12, Serial No.72, Dec. 2019                                                                                         10600 
48.69+28.78pg/ml while it was 
12.99+5.70pg/ml in the control group. It 
was argued that measurement of IFN-γ 
production is helpful to diagnose active TB 
yet additional studies are still needed (12). 
Condos et al. reported that IFNγ signal 
transduction system is functionally normal 
in the alveolar macrophages of TB patients 
(29). Similar to the present study, in some 
studies a significant relationship has been 
noted between IL and IFN deficiency in 
children experiencing severe 
complications of BCG vaccination in 
northern Iran (18). IL-17 and IFN-γ levels 
were significantly lower while IL-4 level 
was higher in patients suffering from 
active TB (25). We should have 
considered the role of other cytokines in 
our study as well. Perhaps the deficiency 
of or changes in other factors and the 
immunity level of children in the region 
have confounded our findings. It should be 
noted that the diagnosis of TB is difficult 
in patients with BCG lymphadenitis.  
Tuberculin skin test (TST) is not useful for 
the diagnosis of BCG lymphadenitis. TST 
is expected to be positive after recent BCG 
vaccination in a person with complete 
immunity. BCG lymphadenitis is 
characterized by positive TST and, if 
necessary, negative IGRAs test, 
accompanied by normal X-ray chest, no 
fever, and unilateral involvement of lymph 
nodes (mostly in the armpit). TB 
specimens isolated from the armpit lymph 
nodes are rare (8, 13).  
Studies regarding the diagnostic accuracy 
of IGRA for TB lymphadenitis have 
reported contradictory results. The 
contradiction of previous studies' findings 
can be, to some extent, attributed to small 
sample size of separate studies indicating 
lack of statistical power. The diagnostic 
value of IGRA differed by different IGRA 
methods, clinical courses ethnicity and 
lymphadenitis location (30). It should be 
noted that the IGRA method is based on 
the response of T lymphocytes susceptible 
to specific Mtb antigens, i.e., ESAT-6 and 
CEP10 (Culture Filtrate Protein (10). 
These antigens are encoded on genes 
located in region of difference 1; Mtb. The 
gene is absent in M. bovis, BCG and most 
NTMs, and therefore has lower cross 
reactivity in BCG-vaccinated individuals 
and does not secrete IFN-γ (31). 
Consequently the probability of false 
positive results is extremely low in the 
IGRA test (24). IGRAs are more specific 
and are not affected by BCG vaccination 
(32). IFN-γ deficiency has been reported in 
patients with acquired immunodeficiency 
syndrome (AIDS), and patients with 
primary immunodeficiency disorder. 
Disseminated BCG infections have also 
been reported in patients with 
immunodeficiency (21, 33).  
Therefore, the deficiency may be 
associated with systemic complications of 
disseminated BCG infections. In the 
present study, there was no significant 
difference in PBMC between the BCG 
lymphadenopathy and control groups 
(P<0.05). Farhondi et al. studied 
disseminated BCG infection in 40 patients. 
In that study, IFN-γR or CD119 was 
checked in six patients, one of whom was 
diagnosed with IFN-γR deficiency using 
flow cytometry (17). A study showed that 
defective IFN-γ pathway cannot be the 
only cause of clinical TB in most cases. 
This study shows that PBMCs in clinical 
TB patients had normal responsiveness to 
IFN-γ and that no known genetic 
mutations were present in the IFN-γR1 and 
STAT1 genes (16).  
The prognosis of patients with IFN-γR1 
deficiency is poor and IFN-γ therapy is not 
effective because of lack of functional 
receptors (18, 20). Bone marrow 
transplantation is the only effective 
treatment for children suffering from 
complete IFN-γR deficiency (34). In our 
study, no relationship was observed 
between IFN-γ receptor and 
lymphadenopathy. The results of various 
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studies should also be compared taking 
into account the measurement methods 
used. In this study ELISA was used for 
IFN-γ and flow cytometry for IFNγ-R. 
Despite numerous studies, because the 
underlying cause of the development of 
this condition is unknown in some people, 
careful examination of immune responses 
greatly assists in finding out the cause of 
its complications. Given the substantial 
role of the immune system in the 
development of complications after BCG 
vaccination, especially severe axillary 
lymphadenitis, and that BCG is injected at 
advanced ages, family history of 
immunodeficiency should also be taken 
into account. If the immune system of the 
infant is weak, the vaccination could be 
delayed (35).  
4-1. Limitations of the study 
The sample size was relatively low due to 
the small number of individuals who 
enrolled in the case group and sampling 
from different populations is preferable. 
5- CONCLUSION 
      IFN-γ level was significantly lower in 
the BCG lymphadenopathy group than in 
the control group, indicating the role of 
this cytokine in developing this disease. In 
BCG vaccine induced axillary 
lymphadenopathy, it seems that the role of 
IFN-γ in interacting with other cytokines 
and other immune cells should be 
investigated. The levels of IFN-γR (CD119 
level in PBMC) in the two groups did not 
show a significant relationship, which 
could be due to the rare incidence of IFN-
γR deficiency in the studied population.  
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